BN Business News
Add your company to Business Communicator →

Business · 15/08/2024Updated: 10/17/2026 · 1 min read

Cubist Pharmaceuticals LLC Withdraws Approval of New Drug Application for ENTEREG Capsules

Summary

The FDA is withdrawing approval of a new drug application for ENTEREG (alvimopan) Capsules, 12 milligrams, after Cubist Pharmaceuticals notified the Agency that the drug product is no longer being marketed.

Original source language: Federal Register — Food and Drug AdministrationOpen original release →

Explore insights

Business insights →